Sagent Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C11474)
◆英語タイトル:Sagent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11474
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Sagent Pharmaceuticals Inc (Sagent), formerly Sagent Holding Co, a subsidiary of Nichi-Iko Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and manufactures injectable products. The company offers products such as amikacin sulfate injection, USP, ampicillin and sulbactam for injection, ampicillin for injection, USP, azithromycin for injection, cefazolin for injection, USP, cefepime for injection, acetazolamide for injection, and adenosine injection. It also offers busulfan injection and pentobarbital sodium injection, USP. The company provides its products in injection and oral dosage forms. It markets its products across the US. Sagent is headquartered in Schaumburg, Illinois, the US.

Sagent Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sagent Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 12
Equity Offering 13
Sagent Pharma Completes Public Offering Of Shares For US$75.3 Million 13
Acquisition 15
Nichi-iko Pharma Acquires Sagent Pharma for USD734.2 Million in Tender Offer 15
Hong Kong King-Friend Pharmaceutical Acquires 100% Stake in Sagent (China) Pharma From Sagent Pharma 17
Sagent Pharma Acquires Omega Labs for USD85.3 Million 18
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 20
Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 21
Sagent Pharmaceuticals Inc – Key Competitors 22
Sagent Pharmaceuticals Inc – Key Employees 23
Sagent Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Joint Venture 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sagent Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Sagent Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 12
Sagent Pharma Completes Public Offering Of Shares For US$75.3 Million 13
Nichi-iko Pharma Acquires Sagent Pharma for USD734.2 Million in Tender Offer 15
Hong Kong King-Friend Pharmaceutical Acquires 100% Stake in Sagent (China) Pharma From Sagent Pharma 17
Sagent Pharma Acquires Omega Labs for USD85.3 Million 18
Zhejiang Hisun Pharma Plans to Divest Stake in Sagent Pharma 20
Sagent Pharma Acquires Remaining 50% JV Stake in Kanghong Sagent from Chengdu Kanghong Pharma for USD25 Million 21
Sagent Pharmaceuticals Inc, Key Competitors 22
Sagent Pharmaceuticals Inc, Key Employees 23
Sagent Pharmaceuticals Inc, Subsidiaries 24
Sagent Pharmaceuticals Inc, Joint Venture 24

List of Figures
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sagent Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sagent Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Sagent Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報(Sagent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆